50 results about "Folate Receptor Alpha" patented technology

The invention provides a monoclonal antibody of a targeted human folate receptor alpha (FR1). Specifically, a mouse is immunized through FR1 recombinant protein, and a monoclonal antibody with high affinity to FR1 is screened out. In addition, the invention also provides an amino acid sequence of the monoclonal antibody, nucleic acid containing the sequence, a carrier or a conjugate containing the nucleic acid, and application of the monoclonal antibody in FR1 overexpressed tumors / cancers.

The invention provides a monoclonal antibody targeting a human folate receptor alpha subtype. Specifically, a mouse is immunized through FR1 recombinant protein, and a monoclonal antibody with high affinity to FR1 is screened out. In addition, the invention also provides an amino acid sequence of the monoclonal antibody, nucleic acid containing the sequence, a carrier or a conjugate containing the nucleic acid, and application of the monoclonal antibody in FR1 overexpressed tumors / cancers.

Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3ζ segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FRα) and a segment that that can specifically bind to a human CD3□ segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.

Antibody constructs that bind human folate receptor alpha (FRα or FOLR1) and antibody-drug conjugates (ADCs) comprising an anti-FRα antibody construct conjugated to a drug, such as a cytotoxin or an immune modulator, and their use as therapeutics or diagnostics, for example, in the treatment or diagnosis of cancer.

This disclosure describes nucleic acids that encode proteins that specifically bind human folate receptor alpha (FRalpha) with high affinity. These proteins include a recombinant human anti-FRalpha IgG1 that is suitable for use as a therapeutic antibody to treat cancers that express FRalpha. Other FRalpha-binding proteins are also described including antibody fragments, antibody conjugates, and fusion proteins.

The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.

A method for predicting the efficacy of an antibody drug conjugate (ADC) therapy involves determining the mean optical density (OD) of membrane and optionally cytoplasm staining of each cancer cell in a whole slide image. A diagnostic antibody to which a dye is linked targets the same folate receptor alpha protein as does the ADC antibody. Statistical operations are performed on the OD of staining, such as computing the median, absolute deviation, difference in OD of membrane and cytoplasm staining, percentage of cells a minimum OD, or the sum of minimally stained cells plus insufficiently stained cells near stained cells. For example, a zero, high or low ADC dosage is recommended based on whether median OD falls below, between or above two OD thresholds, respectively. The upper and lower OD thresholds are correlated to responses of training patients treated with the ADC and whose stained cancer tissue has been analyzed.

This disclosure describes methods and drug therapies for treating or preventing various health conditions, including cancer. The methods and therapies of the present disclosure comprise antibody-based therapies that functionally increase antibody binding to target antigens. Specifically, the antibody-based therapies increase the copy number of an antigen by utilizing at least a pair of differing antibodies directed at non-overlapping epitopes of the same antigen for effectively delivering payloads to a target cell. Each differing antibody may be conjugated to the same or a differing payload. The antibody-based therapy may use proteins that specifically bind human folate receptor alpha (FRalpha) with high affinity. These proteins include a human anti-FRalpha IgG1 that is suitable for use as a therapeutic antibody to treat conditions, such as cancers that express FRalpha. Other FRalpha-binding proteins are also described including antibody fragments, antibody conjugates, and fusion proteins.

Antibodies specific to folate receptor alpha (a.k.a. folate receptor 1 or FOLR1) and uses thereof for therapeutic and diagnostic purposes. Also provided herein are chimeric antigen receptors (CARs) comprising an extracellular antigen-binding fragment that binds FOLR1 and immune cells expressing such.

Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FRα) (an anti-FRα antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.

This disclosure describes proteins that specifically bind human folate receptor alpha (FRalpha) with high affinity. These proteins include a recombinant human anti-FRalpha IgG1 that is suitable for use as a therapeutic antibody to treat cancers that express FRalpha. Other FRalpha-binding proteins are also described including antibody fragments, antibody conjugates, and fusion proteins.

The present application provides a monoclonal antibody targeting human folate receptor alpha subtype. Specifically, the present application immunizes mice with FR1 recombinant protein, and screens monoclonal antibodies with high affinity to FR1. In addition, the present application also provides the amino acid sequence of the monoclonal antibody, nucleic acid containing the sequence, vector or conjugate containing the nucleic acid, and the application of the monoclonal antibody in FR1 overexpressed tumors / cancers.

Provided are anti-FOLR1 (folate receptor alpha) antibodies, antigen-binding fragments thereof, and antibody-drug conjugate (ADC) derived therefrom; and anti-FOLR1 / MUC1 (e.g., multispecific or bispecific) antibodies or antigen-binding fragments thereof, and antibody-drug conjugate (ADC) derived therefrom and uses thereof.

Bispecific antibodies that bind to folate receptor alpha (FRα) and NaPi2b, conjugates comprising the bispecific antibodies conjugated to one or more drug moieties and methods of using the antibodies and conjugates in the treatment of cancers expressing FRα, NaPi2b or both FRα and NaPi2b.

There remains a need for more effective methods and dosing regimens for treating subjects with FRA-expressing cancers with anti-FRA ADCs, such as MORAb-202, e.g., that reduce the side effects of treatment. [Solution] Linker toxins and antibody-drug conjugates are disclosed that bind to human oncology antigen targets, such as folate receptor alpha, and / or provide anti-tubulin drug activity. The linker toxins and antibody-drug conjugates contain an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in treating cancer by administering the antibody-drug conjugates provided herein.

Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and / or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

To provide an effective antibody-drug conjugate comprising an anti-FRα antibody, with high specificity, low toxicity (improved therapeutic index) and differentiated mechanism of action of the payload.SOLUTION: Provided is an antibody-drug conjugate in which the antibody specifically binds to folate receptor alpha (FRα) and in which the drug is selected from topoisomerase I inhibitors, camptothecin analogs such as exatecan. Such an antibody-drug conjugate is especially useful for treating proliferative diseases including cancers such as ovarian, breast or lung cancer.SELECTED DRAWING: None

This disclosure describes proteins that specifically bind human folate receptor alpha (FRalpha) with high affinity. These proteins include a recombinant human anti-FRalpha IgG1 that is suitable for use as a therapeutic antibody to treat cancers that express FRalpha. Other FRalpha-binding proteins are also described including antibody fragments, antibody conjugates, and fusion proteins.

Provided are antibody-drug conjugates (ADCs) comprising an antibody construct that specifically binds to human folate receptor alpha (FRα) (anti-FRα antibody construct) conjugated to a camptothecin analog of formula (I), which are useful as therapeutic agents, particularly in the treatment of cancer. TIFF2025510791000395.tif53165

This disclosure describes methods and drug therapies for treating or preventing various health conditions, including cancer. The methods and therapies of the present disclosure comprise antibody-based therapies that functionally increase antibody binding to target antigens. Specifically, the antibody-based therapies increase the copy number of an antigen by utilizing at least a pair of differing antibodies directed at non-overlapping epitopes of the same antigen for effectively delivering payloads to a target cell. Each differing antibody may be conjugated to the same or a differing payload. The antibody-based therapy may use proteins that specifically bind human folate receptor alpha (FRalpha) with high affinity. These proteins include a human anti-FRalpha IgG1 that is suitable for use as a therapeutic antibody to treat conditions, such as cancers that express FRalpha. Other FRalpha-binding proteins are also described including antibody fragments, antibody conjugates, and fusion proteins.

The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FRα) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FRα and modulate FRα activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FRα and modulates FRα activity.

The invention belongs to the field of antibody drugs, and relates to a folate receptor alpha (FR alpha) targeting antibody, a bispecific antibody and a conjugate, and preparation and application thereof.

The present disclosure provides methods of treating patients with cancers that express folate receptor alpha (FRα), e.g., a recurrent platinum-sensitive ovarian cancer (rPSOC), comprising administering to the patient an anti-FRα immunoconjugate.

Provided are antibody-drug conjugates (ADCs) comprising an antibody construct that specifically binds to human folate receptor alpha (FRα) (anti-FRα antibody construct) conjugated to a camptothecin analog of formula (I), which are useful as therapeutic agents, particularly in the treatment of cancer. TIFF2025510791000395.tif53165

Antibody-drug conjugates (ADCs) comprising antibody constructs that bind to human folate receptor alpha (FRα or FOLR1) and anti-FRα antibody constructs conjugated to drugs such as cytotoxins or immunomodulators, and their use as therapeutic or diagnostic agents, for example, in the treatment or diagnosis of cancer.

The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FRα) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FRα and modulate FRα activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FRα and modulates FRα activity.     A B S T R A C T 20 26 20 52 05 01 J ul 2 02 6 A B S T R A C T 2 0 2 6 2 0 5 2 0 5 0 1 J u l 2 0 2 6

Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FRα) (an anti-FRα antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.

Bispecific antibodies that bind to folate receptor alpha (FRα) and NaPi2b, conjugates comprising the bispecific antibodies conjugated to one or more drug moieties and methods of using the antibodies and conjugates in the treatment of cancers expressing FRα, NaPi2b or both FRα and NaPi2b.

The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.

Provided are modified cells and methods for their use in treating cancer. The cells are modified to express and secrete a Bi-specific T cell engager (BiTE) that includes a segment that specifically binds to human Folate Receptor alpha (FRα) and a segment that that specifically binds to human CD3, such as CD3e. The modified cells can be T cells. Methods for producing the modified cells are also provided.